175 related articles for article (PubMed ID: 1847128)
1. N2 (clinical) non-small cell carcinoma of the lung: prospective trials of radiation therapy with total doses 60 Gy by the Radiation Therapy Oncology Group.
Cox JD; Azarnia N; Byhardt RW; Shin KH; Emami B; Perez CA
Int J Radiat Oncol Biol Phys; 1991 Jan; 20(1):7-12. PubMed ID: 1847128
[TBL] [Abstract][Full Text] [Related]
2. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11.
Cox JD; Azarnia N; Byhardt RW; Shin KH; Emami B; Pajak TF
J Clin Oncol; 1990 Sep; 8(9):1543-55. PubMed ID: 2167952
[TBL] [Abstract][Full Text] [Related]
3. Impact of adding concurrent chemotherapy to hyperfractionated radiotherapy for locally advanced non-small cell lung cancer (NSCLC): comparison of RTOG 83-11 and RTOG 91-06.
Komaki R; Scott C; Lee JS; Urtasun RC; Byhardt RW; Emami B; Andras EJ; Asbell SO; Rotman M; Cox JD
Am J Clin Oncol; 1997 Oct; 20(5):435-40. PubMed ID: 9345325
[TBL] [Abstract][Full Text] [Related]
4. Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88-08/ECOG 4588. Radiation Therapy Oncology Group. Eastern Cooperative Oncology Group.
Komaki R; Scott CB; Sause WT; Johnson DH; Taylor SG; Lee JS; Emami B; Byhardt RW; Curran WJ; Dar AR; Cox JD
Int J Radiat Oncol Biol Phys; 1997 Oct; 39(3):537-44. PubMed ID: 9336129
[TBL] [Abstract][Full Text] [Related]
5. Interfraction interval does not affect survival of patients with non-small cell lung cancer treated with chemotherapy and/or hyperfractionated radiotherapy: a multivariate analysis of 1076 RTOG patients.
Werner-Wasik M; Scott C; Graham ML; Smith C; Byhardt RW; Roach M; Andras EJ
Int J Radiat Oncol Biol Phys; 1999 May; 44(2):327-31. PubMed ID: 10760427
[TBL] [Abstract][Full Text] [Related]
6. A phase I/II study to evaluate accelerated fractionation via concomitant boost for squamous, adeno, and large cell carcinoma of the lung: report of Radiation Therapy Oncology Group 84-07.
Byhardt RW; Pajak TF; Emami B; Herskovic A; Doggett RS; Olsen LA
Int J Radiat Oncol Biol Phys; 1993 Jun; 26(3):459-68. PubMed ID: 8390420
[TBL] [Abstract][Full Text] [Related]
7. Five-year survival after hyperfractionated radiation therapy for non-small-cell carcinoma of the lung (NSCCL): results of RTOG protocol 81-08.
Cox JD; Pajak TF; Herskovic A; Urtasun R; Podolsky WJ; Seydel HG
Am J Clin Oncol; 1991 Aug; 14(4):280-4. PubMed ID: 1650526
[TBL] [Abstract][Full Text] [Related]
8. Phase III study comparing chemotherapy and radiotherapy with preoperative chemotherapy and surgical resection in patients with non-small-cell lung cancer with spread to mediastinal lymph nodes (N2); final report of RTOG 89-01. Radiation Therapy Oncology Group.
Johnstone DW; Byhardt RW; Ettinger D; Scott CB
Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):365-9. PubMed ID: 12243809
[TBL] [Abstract][Full Text] [Related]
9. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
10. Dose intensity of radiation therapy in non-small cell carcinoma of the lung: a review of RTOG data and strategies.
Cox JD; Sause WT; Byhardt RW; Komaki R; Perez CA; Pajak TF
Lung Cancer; 1994 Mar; 10 Suppl 1():S161-6. PubMed ID: 8087506
[TBL] [Abstract][Full Text] [Related]
11. Analysis of early and late deaths on RTOG non-small cell carcinoma of the lung trials: comparison with CALGB 8433.
Komaki R; Pajak TF; Byhardt RW; Emami B; Asbell SO; Roach M; Pedersen JE; Curran WJ; Lattin P; Russell AH
Lung Cancer; 1993 Dec; 10(3-4):189-97. PubMed ID: 8075966
[TBL] [Abstract][Full Text] [Related]
12. Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung: analysis of 1244 cases from 3 Radiation Therapy Oncology Group (RTOG) trials.
Cox JD; Pajak TF; Asbell S; Russell AH; Pederson J; Byhardt RW; Emami B; Roach M
Int J Radiat Oncol Biol Phys; 1993 Oct; 27(3):493-8. PubMed ID: 8226140
[TBL] [Abstract][Full Text] [Related]
13. Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung.
Byhardt RW; Scott C; Sause WT; Emami B; Komaki R; Fisher B; Lee JS; Lawton C
Int J Radiat Oncol Biol Phys; 1998 Oct; 42(3):469-78. PubMed ID: 9806503
[TBL] [Abstract][Full Text] [Related]
14. Three-dimensional conformal radiation therapy for non-small-cell lung cancer: a phase I/II dose escalation clinical trial.
Wu KL; Jiang GL; Liao Y; Qian H; Wang LJ; Fu XL; Zhao S
Int J Radiat Oncol Biol Phys; 2003 Dec; 57(5):1336-44. PubMed ID: 14630271
[TBL] [Abstract][Full Text] [Related]
15. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma.
Bradley J; Graham MV; Winter K; Purdy JA; Komaki R; Roa WH; Ryu JK; Bosch W; Emami B
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):318-28. PubMed ID: 15667949
[TBL] [Abstract][Full Text] [Related]
16. Quality of Life Analysis of a Radiation Dose-Escalation Study of Patients With Non-Small-Cell Lung Cancer: A Secondary Analysis of the Radiation Therapy Oncology Group 0617 Randomized Clinical Trial.
Movsas B; Hu C; Sloan J; Bradley J; Komaki R; Masters G; Kavadi V; Narayan S; Michalski J; Johnson DW; Koprowski C; Curran WJ; Garces YI; Gaur R; Wynn RB; Schallenkamp J; Gelblum DY; MacRae RM; Paulus R; Choy H
JAMA Oncol; 2016 Mar; 2(3):359-67. PubMed ID: 26606200
[TBL] [Abstract][Full Text] [Related]
17. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer.
Sause WT; Scott C; Taylor S; Johnson D; Livingston R; Komaki R; Emami B; Curran WJ; Byhardt RW; Turrisi AT
J Natl Cancer Inst; 1995 Feb; 87(3):198-205. PubMed ID: 7707407
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase II chemotherapy and radiotherapy trial for patients with locally advanced inoperable non-small-cell lung cancer: long-term follow-up of RTOG 92-04.
Komaki R; Seiferheld W; Ettinger D; Lee JS; Movsas B; Sause W
Int J Radiat Oncol Biol Phys; 2002 Jul; 53(3):548-57. PubMed ID: 12062596
[TBL] [Abstract][Full Text] [Related]
19. Randomized study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable nonsmall cell lung cancer: Radiation Therapy Oncology Group (RTOG) 92-04.
Komaki R; Scott C; Ettinger D; Lee JS; Fossella FV; Curran W; Evans RF; Rubin P; Byhardt RW
Int J Radiat Oncol Biol Phys; 1997 Apr; 38(1):149-55. PubMed ID: 9212017
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase I study of standard-fractionated or accelerated-hyperfractionated radiotherapy with concurrent cisplatin and vindesine for unresectable non-small cell lung cancer: a report of Japan Clinical Oncology Group Study (JCOG 9601).
Tsuchiya S; Ohe Y; Sugiura T; Fuwa N; Kitamoto Y; Mori K; Kobayashi H; Nakata K; Sawa T; Hirai K; Etoh T; Saka H; Saito A; Fukuda H; Ishizuka N; Saijo N;
Jpn J Clin Oncol; 2001 Oct; 31(10):488-94. PubMed ID: 11696618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
